EP1858573A1 — Inhalation devices
Assigned to Glaxo Group Ltd · Expires 2007-11-28 · 18y expired
What this patent protects
An inhaler for delivering medicament by inhalation comprises a canister (305) and an actuator comprising a housing (311) receiving the canister, and an actuation mechanism (309) for actuating the canister (305). The actuation mechanism (309) comprises a loading member (361) which…
USPTO Abstract
An inhaler for delivering medicament by inhalation comprises a canister (305) and an actuator comprising a housing (311) receiving the canister, and an actuation mechanism (309) for actuating the canister (305). The actuation mechanism (309) comprises a loading member (361) which is fitted to the head of the canister body (323) and includes a loading section (375) which is in use, acted upon to drive the loading member (361) in an actuating direction from a rest position to an actuated position in which the canister (305) is actuated to deliver medicament. The actuation mechanism further comprises at least one actuating member (363a, b) which is actuatable by a user to drive the loading member (361) in the actuating direction to the actuated position. The at least one actuating member (363a, b) is pivotally coupled to the housing (311) and comprises a gripping element (377) which is configured to be gripped and depressed by the user in actuating the canister (305).
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.